Thrombocytopenia Treatment Market

Thrombocytopenia Treatment Market Snapshot (2023 to 2033)

During the projected period from 2023 to 2033, the global market for thrombocytopenia treatment is conjectured to surge at a CAGR of 5.2%. In 2033, the industry is forecasted to reach a valuation of USD 10 Billion from USD 6 Billion in 2023. Increased thrombocytopenia morbidity and mortality rates, inexpensive thrombocytopenia therapy, and rising knowledge of thrombocytopenia and its treatment are among the reasons driving the worldwide thrombocytopenia treatment market.

Blood clots are due to platelets in the blood. Thrombocytopenia is defined as an abnormally low platelet count in the blood due to the presence of any illness or ailment. Individuals with thrombocytopenia have delayed or no blood clotting. Because of the high prevalence of thrombocytopenia and growing knowledge of treatment alternatives, the worldwide thrombocytopenia treatment market is likely to grow considerably in the near future.

Thrombocytopenia symptoms include nosebleeds, bruises, redness, and bleeding in the gums and mouth. Thrombocytopenia is discovered using tests such as a complete blood count (CBC) and a blood clotting study. Furthermore, biopsy and bone marrow aspiration are used to diagnose thrombocytopenia. According to a study published in Professional Med J in 2014 titled Incidence of Thrombocytopenia, the prevalence of thrombocytopenia is greater in persons aged 60 years and older who had non-cirrhotic liver disease. However, rapid discovery, along with the capacity to clone thrombopoietin, has resulted in novel therapeutic worldwide treatment options.

Data Points	Key Statistics
Expected Market Value (2023)	USD 6 Billion
Anticipated Forecast Value (2033)	USD 10 Billion
Projected Growth Rate (2023 to 2033)	5.2% CAGR

Thrombocytopenia Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for thrombocytopenia treatment is projected to increase at a CAGR of 5.2% during the forecast period between 2023 and 2033, reaching a total of USD 10 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 4%.

Due to the high prevalence of thrombocytopenia and increased knowledge about treatment alternatives, the worldwide thrombocytopenia treatment market is likely to grow considerably in the near future. Stringent regulatory clearances, on the other hand, and thrombocytopenia diagnostic delays are factors restricting the worldwide thrombocytopenia treatment market.

Which are Some Prominent Drivers of Thrombocytopenia Treatment Market?

The Approval of Efficient and Safe Medications for Thrombocytopenia Therapy will provide the Thrombocytopenia Treatment Industry with a Boost

Treatment approaches are generally tailored to the underlying cause of thrombocytopenia. The underlying reason for thrombocytopenia is not always understood, especially in situations of severe bleeding. Shionogi Inc.'s Lusutrombopag, an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist, was approved by Japan's Pharmaceuticals and Medical Devices Agency in September 2015.

Lusutrombopag improved chronic liver disease (CLD) linked with thrombocytopenia in individuals undergoing invasive operations. Lusustrombopag operates exclusively on human thrombopoietin (TPO) receptors, stimulating signaling pathways that cause bone marrow cells to proliferate and differentiate into megakaryocytes. As a result, the blood platelet count rises. Patients using Lusustrombopag, on the other hand, had greater blood leukocyte and erythrocyte counts.

Furthermore, Rigel Pharmaceuticals, Inc. submitted an application to the FDA in June 2017 for a new oral experimental medication, Tavalisse (fostamatinib disodium). This medication is intended to treat individuals with chronic or persistent immune thrombocytopenia by inhibiting the spleen tyrosine kinase.

Another Novartis medicine, Eltrombopag, an oral, non-peptide thrombopoietin receptor agonist, has proven effectiveness and safety in individuals with persistent immune thrombocytopenia (CIT). This medication is licensed in the United States and registered in Europe. Eltrombopag at low dosage is effective and safe for CIT prevention. Long-term use of thrombopoietin (TPO) receptor agonists is safe for patients with chronic lymphocytic leukemia accompanied by immune thrombocytopenia, according to Case Reports Hematology, because they are non-immunosuppressive medications.

Growing Prevalence of Thrombocytopenia to Accelerate Market Growth

The global incidence of thrombocytopenia is driving the thrombocytopenia therapy market. Chronic Hepatitis C patients are at a substantially increased risk of developing thrombocytopenia. According to the World Health Organization (WHO), the prevalence of Hepatitis C was lower in the Americas and Europe in 2014 compared to Africa and Pakistan, where the incidence of chronic liver disease was 4-6% higher. Liver disease has emerged as a socioeconomic and worldwide health issue, affecting 60-80% of the population.

Furthermore, rising government support for fast-track approval in order to discover newer treatments for this disorder, as well as capital investments in the creation of new drugs by biotechnology and pharmaceutical companies, are expected to drive growth in the thrombocytopenia treatment market over the coming years.

Which are the Trough Areas faced by the Thrombocytopenia Treatment Market?

Patent Expiration is a Key Obstacle, Stifling the Market Growth

The thrombocytopenia treatment market is predicted to slow considerably in 2023 due to patent expiry and the rising availability of generic Promacta and MabThera.

Region-wise Insights

 How will Thrombocytopenia Treatment Market Demand progress in the Asia Pacific?

Rapidly Increasing Medical Tourism Business in Asia Pacific Widening Profit Margins

The Asia Pacific region is a particularly appealing market for thrombocytopenia treatment. Factors such as the rapidly increasing medical tourism business in Asia Pacific, particularly in India and China, are likely to draw patients from all over the world for treatment. The presence of a large patient pool in the Asia Pacific is likely to raise the risk of morbidity associated with thrombocytopenia in the area.

Furthermore, initiatives taken by governments in Asia Pacific countries to promote the healthcare sector in these countries benefits from foreign currency differences, and the availability of skilled and qualified workforce are among the factors expected to attract global players to the Asia Pacific thrombocytopenia treatment market in the near future. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 4.9% in the assessment period 2023 to 2033.

How attractive are Growth Prospects for Thrombocytopenia Treatment in North America?

Strong Lab Infrastructure and Fast Expanding Research in Anticoagulant Medicines

North America has seen significant revenue opportunities as a result of strong lab infrastructure and fast-expanding research in anticoagulant medicines. Pathophysiology has also benefited the area's healthcare system.

Growing public knowledge of the morbidity and mortality associated with heparin treatment in patients, particularly in heart surgery operating rooms, has hampered research in nations such as the United States. North America is expected to grow at a CAGR of 5.1% in the assessment period 2023 to 2033.

What Factors favoring the Growth of Thrombocytopenia Treatment in Europe?

Favorable Reimbursement Policies fuelling sales of Thrombocytopenia Treatment

Europe is the second leading market in thrombocytopenia treatments. The morbidity rate caused by thrombocytopenia is high in affluent nations, whereas the fatality rate is high in poor countries.

Favorable reimbursement policies, high healthcare spending, a well-structured regulatory framework, a high rate of compliance with defined regulations, the availability of highly advanced healthcare facilities, and high awareness of thrombocytopenia and its treatment are some of the factors propelling the thrombocytopenia treatment market in Europe. Thus, owing to the aforementioned reasons, the region is expected to grow at a CAGR of 5% in the assessment period 2023 to 2033. 

Category-wise Insights

 Which is the Most Preferred Drug Class Segment?

The Glucocorticoids Segment to enhance Sales Prospects

On the basis of drug class, the thrombocytopenia treatment market is segmented into glucocorticoids, lysosomal enzymes, and platelet-stimulating agents. Glucocorticoids are expected to hold the largest share of the market.

Glucocorticoids are the usual first-line therapy for people with immune thrombocytopenic purpura (ITP) because of their efficacy in boosting platelet count, cheap cost, and ease of administration.

Which is the Most Popular Distribution Channel in the Thrombocytopenia Treatment Market?

The Hospital Pharmacies Segment to Drive the Market Growth

On the basis of distribution channels, the thrombocytopenia treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to hold the lion’s share in the market due to their low price and easy availability.

On the other hand, the online pharmacies segment is likely to gain momentum during the forecast period, due to hefty discounts amid the soaring e-commerce sector. 

Start-ups offering Thrombocytopenia Treatment

Key start-up players in the thrombocytopenia treatment are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. One of the key thrombocytopenia treatment start-ups is as follows:

Sexton Biotechnologies is a firm headquartered in the United States that creates human platelet lysate products. Pathogen-free human platelet lysates (GPL) are a medium that lowers risks and increases downstream performance when compared to alternatives. Signata, the startup's gene therapy platform, uses closed automation to limit contamination concerns, gather batch records, and regulate operations with a flexible system.

Market Competition

The thrombocytopenia treatment industry has experienced potential clinical breakthroughs as a result of ongoing guidelines changes. The 2018 American Society of Hematology (ASH) Guideline recommended a variety of alternative anticoagulant alternatives for doctors to consider.

Current practice recommendations in industrialized countries have prompted the development of novel thrombin inhibitors and immunoassays. This has increased therapy possibilities for acute thrombocytopenia treatment. Top players intend to introduce new anticoagulants to improve healthcare team outcomes. Manufacturers of assays and pharmaceuticals are focusing on lowering the probability of thromboembolic consequences.

Key players in the thrombocytopenia treatment market are 3SBio Inc., Amgen Inc., Takeda Pharmaceutical Company, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd. and Merck & Co., Inc.

Recent Developments:

In December 2021, Horizon Therapeutics Plc's board of directors and Amgen Inc.'s board of directors announced that they have agreed on the terms of a cash offer for the Company by Pillartree Limited (Acquirer Sub), a newly formed private limited company wholly owned by Amgen, which is unanimously recommended by the Company Board and pursuant to which Acquirer Sub will acquire the entire issued and to be issued

In December 2020, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., a subsidiary of 3SBio Inc., and Verseau Therapeutics, Inc. announced the selection of a monoclonal antibody targeting VSIG4 as a license program under their partnership arrangement aimed at the creation and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a variety of cancers.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 6 Billion
Market Value in 2033	USD 10 Billion
Growth Rate	CAGR of 5.2% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Drug Class, Distribution Channel, Region
Regions Covered	North America; Latin America; Europe; Asia Pacific; Middle East and Africa
Key Countries Profiled	The USA, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC, South Africa, Israel
Key Companies Profiled	3SBio Inc.; Amgen Inc.; Takeda Pharmaceutical Company; Bayer AG; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Hansa Medical AB; Intas Pharmaceuticals Ltd.; Merck & Co. Inc.
Customization	Available Upon Request

Key Segments Profiled in the Thrombocytopenia Treatment Industry Survey

By Drug Class:

• Glucocorticoids
• Lysosomal Enzyme
• Platelet Stimulating Agent

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Frequently Asked Questions

What is the Demand Driver of the Thrombocytopenia Treatment Market?

The approval of efficient and safe medications for thrombocytopenia therapy is expected to drive the market demand.

What Limits the Growth of the Thrombocytopenia Treatment Market?

Patent expiry and the rising availability of generic Promacta and MabThera limit the growth potential.

How will Thrombocytopenia Treatment Market Demand Progress in North America?

Strong lab infrastructure and fast-expanding research in anticoagulant medicines will aid growth at a CAGR of 5.1% in North America.

Which is the Globally Preferred Drug Class Segment?

Based on drug class, glucocorticoids are expected to hold a significant market position.

What is the Competitive Strategy Adopted by Key Players?

Key players intend to introduce new anticoagulants to improve healthcare team outcomes.